Dear Colleagues,
“Beware the Ides of March” warned a soothsayer to Julius Caesar in William Shakespeare’s Julius Caesar. The prophecy proved fatal when Caesar was assassinated in mid-March. While the specificity of that date was likely poetic license, the Ides of March has since become synonymous with foreboding. Historically, however, it was a day of reflection and transition, and this year it coincided with a series of significant legal rulings related to healthcare policy and administrative processes.
On March 16, the U.S. District Court for the District of Massachusetts issued a ruling concerning the appointment process for members of the Advisory Committee on Immunization Practices (ACIP) and paused implementation of related actions pending further review. Later that week, the U.S. District Court for the District of Oregon addressed procedural considerations related to federal policy on gender-affirming care, with implications for how services may be supported under federal programs.
Circling back to Julius Caesar: In Commentarii de Bello Gallico (Commentaries on the Gallic War), he observed, “In most cases men willingly believe what they wish.” These developments underscore the importance of established legal and regulatory processes in shaping healthcare policy. As a community grounded in science and clinical care, we recognize that medical decision-making is most effective when informed by evidence, careful review, and appropriate governance.
I share these updates to keep our members informed of developments that may impact clinical practice and the broader healthcare environment. This month, in addition to new medications and drug warnings, the Drugs & Therapeutics Committee has created a resource on Long-Acting Growth Hormone products that can be found in the PES Clinical Resource Library.
Laurie E. Cohen, MD
President, PES Board of Directors
Congratulations to the 2026 Karger Prize Winners
Best Review Article: Management of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in Neonates and Infants | Hormone Research in Paediatrics | Karger Publishers author Hannah Pearlstein, MD
Best Original Research Article: Type 1 Diabetes Polygenic Scores Improve Diagnostic Accuracy in Pediatric Diabetes Care | Hormone Research in Paediatrics | Karger Publishers Raymond Joseph Kreienkamp, MD
Invitation from the RAC: NEW! Specific Aims Page Review
The Research Affairs Committee (RAC) is launching a new Specific Aims Page review for PES members preparing a grant submission.
Completed Specific Aims Pages for multi-year extramural grants will be evaluated by two RAC members (who may or may not be experts in the field). Members will provide brief constructive feedback on the aims within approximately two weeks, evaluating significance, clarity, feasibility, and excitement.
We ask that members receiving this service agree to respond to follow-up surveys related to the helpfulness of the reviews and the outcome of the grant. Please visit the submission form on the PES website link below to submit your Specific Aims page today!
Specific Aims Page, Application for Review: Specific Aims Initiative - Pediatric Endocrine Society
D&T New Meds and Tech: DESMODA™ (desmopressin acetate) Oral Solution
Prepared by Daniel Mak, MD
New Meds and Tech: DESMODA™ (desmopressin acetate) Oral Solution - Pediatric Endocrine Society
D&T New Meds and Tech - Navepegritide (Yuviwel®) for Children with Achondroplasia
Written by Anna Ryabets-Lienhard, DO
Edited by Neha Patel, DO and Emily Breidbart, MD
D&T New Meds and Tech - Depo-Provera® and Increased Risk of Meningioma: FDA-Label Update
Written by: Anna Ryabets-Lienhard, DO as part of Drugs and Therapeutics Committee
Depo-Provera® and Increased Risk of Meningioma: FDA-Label Update - Pediatric Endocrine Society
D&T New Meds and Tech - Sogroya® (somapacitan-beco) Injection
Prepared by Daniel Mak, MD; Edited by Neha Patel, DO
Upcoming Online Education
Tuesday, April 14 I 5:30-6:30 PM ET Resister
Wednesday, April 15 I 5:00-6:00 PM ET Register
Visit our education calendar for more information about our online education offerings and to register: Events for April 2026 – Pediatric Endocrine Society
MAP Spotlight
Eton- DESMODA™ (desmopressin acetate) Oral Solution: The first and only FDA-approved oral desmopressin solution
Eton Pharmaceuticals is excited to announce that effective February 25, 2026, the U.S. Food and Drug Administration has approved a New Drug Application for DESMODA™ (desmopressin acetate) Oral Solution: The first and only FDA-approved oral desmopressin solution.
Eton currently commercializes ALKINDI SPRINKLE® (hydrocortisone) oral granules, KHINDIVI™ (hydrocortisone) oral solution, and INCRELEX® (mecasermin). All patient support programs and prescription fulfillment will be managed through Eton Cares and their specialty pharmacy, AnovoRx®.
AnovoRx: Phone: 833-343-2500 Fax: 855-813-2039 Eton will support DESMODA patients with our full complement of Eton Cares services, designed to coordinate rare disease access and coverage so patients can start therapy quickly.
The full range of patient support services include:
- $0 Copay for Eligible Patients
- Enhanced Prior Authorization Support to Help Navigate Access
- Dedicated Care Coordination
- Financial Assistance Review
- Medication Delivery and Therapy-Start Support
- Ongoing Clinical Support
- Nurse Ambassador Support
For more information: www.Desmodahcp.com
Eton Pharmaceuticals is part of the PES Mission Alliance Partnership. This announcement was prepared in compliance with PES guidelines to ensure objective educational content.
Survey Invitation: AI in Pediatric Endocrinology
Artificial intelligence (AI) is a powerful tool that can help reduce clinical workload, enhance both patient and physician experiences, and strengthen our research capabilities. However, many of us still have questions regarding its effectiveness and practical application.
We invite you to take part in this survey, which seeks to evaluate our understanding and use of AI in pediatric endocrinology. This will help us find ways to improve AI adoption in pediatric endocrinology to increase efficiency and productivity.
- Eligibility: Healthcare professionals working in pediatric endocrinology.
- Study Procedures: Participation involves completing an online survey about your experiences and understanding of AI in pediatric endocrinology.
- Location: The survey can be completed remotely via a secure online platform.
- Time Commitment: The survey will take approximately 10 minutes to complete.
- Compensation: No compensation is provided for participation in this study. Your participation is entirely voluntary. If you are interested in taking part, please click the link below to access the survey by Tuesday, April 21, 2026.
Thank you for considering participating in this research study. Your input will help advance the use of AI in pediatric endocrinology.
Click here to take the survey.
PES Fellow Spotlight: Sahaj Singh, MD
Meet Sahaj: March Fellow Spotlight – Sahaj Singh, MD - Pediatric Endocrine Society
From the NIH: New Biographical Sketches and Current & Pending (Other) Support forms.
The NIH continues to update its FAQs on the new Biographical Sketches and Current & Pending (Other) Support forms. See NIH's FAQs on the Common Forms for the latest information.
Health Disparities Spotlight: Recognizing Autism Awareness Month
Submitted by Kate Citron-Zafrin, MD
Health Systems Disparity Initiative - Pediatric Endocrine Society
March Historical Tidbit - Then and Now: This Month in Endocrine History
Submitted by Evan Graber, DO